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Abstract 
Using extensive patent data on Scandinavian Biotech firms together with associated 
firm level data, this paper explores factors that drive the innovative scope of biotech 
firms. Collaborating with pharmaceutical firms, universities and other dedicated biotech 
firms proves beneficiary in introducing innovations broadening the innovation scope of 
biotech firms. Contrasting large and small molecules research firms exhibit noteworthy 
differences in the type of collaboration partner that allows the firm to expand its 
innovative scope. This suggests that biotech firms need to align the partner type with its 
science base if the goal is to produce patents beyond the firms technological boundary. 
Additionally, we find that outsourcing and acquisition of innovations increase their 
scope, lending support to the view that outsourced R&D expands the boundary of the 
firm’s innovative search. 
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Introduction1 
It is beneficial to draw on collaborative partners for knowledge as inputs into the innovation process 
converting it into an interactive and distributed process (see e.g. Von Hippel (1976, 1988), Rothwell 
(1977), Lundvall (1988)). Cooperation has become fundamental in the innovation process. As a 
result the boundaries of the firm have become fuzzy and alliances are almost necessities for a 
successful innovation process (Teece, 1992). The open model has become an essential element of 
the innovation literature. It emphasise that being open to external collaborators allow firms to draw 
on external sources of knowledge and capture opportunities that are inevitably lost when using a too 
internally focused search strategy (Chesbrough, 2003).  
 
That open innovation leads to a higher innovative performance has been argued both theoretically 
(Cohen and Levinthal, 1990) and empirically (Laursen and Salter, 2006). We also know that 
boundary spanning significantly contributes to the impact level of a given innovation (Rosenkopf 
and Nekar, 2001). However, we know little about the degree to which openness extends the 
innovative scope of the firm. Do cooperative arrangements allow firms to innovate in different 
technologies than otherwise? To what extend do the type of collaborating partner shape the 
propensity to introduce innovations that increase the innovative scope of the firm? How does 
externally developed innovation add to the diversity of the firm’s innovations? Finally, are the 
above relations to some degree dependent on the science base of the firm? These are all questions 
we address in the present paper.   
 
Drawing on a comprehensive dataset on Scandinavian biotechnology firms and their patent 
applications, we explore to what extend the innovative scope of a firm may be attributed to its 
                                                 
1 The authors are grateful to Rasmus Lund Jensen and Henrich Dahlgren for extensive help with data handling and understanding the data structure 
and key variables. 
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external innovation linkages. Extracting inventor data in the patent applications and linking these 
with inventor affiliation data provides sufficient information to contrast different partner types 
against each other. By exploiting the affiliation data for inventors we also investigate how 
innovations developed outside the firm play a role in shaping the diversity in the firm’s innovations. 
We discriminate between outsourced innovation activities and acquired patent applications. 
Additionally we look for dissimilarities between two different sciences bases. We distinguish 
between firms that operate in large molecules biotechnology from those that operate in small 
molecule biotechnology.  
 
Understanding the factors that allows a firm to become more exploratory in its innovation activities 
and hence expand its technological diversity is important for several reasons. First, extending the 
knowledge base and the innovative scope of a firm may play a crucial role in shaping its 
performance. Extending into new and for the firm otherwise uncharted technologies will ceteris 
paribus be less likely to lead to cannibalism than innovating narrowly. In particular biotechnology 
firms need to seek knowledge both internally and externally to keep up its performance (Decarolis 
& Deeds, 1999). Second, knowledge creation and innovation leads to overall welfare gains. Not 
least with respect to the biotechnology industry. Third, unravelling the factors that enables a firm to 
shift their innovation activities and expand their technological boundaries also extends our 
understanding of innovation and how firms become innovative.   
 
The article is organised as follows. Section 2 presents the empirical and theoretical evidence on why 
firms need to collaborate to extend their innovation search boundary. Additionally we end the 
section by emphasizing the biotechnology industry and previous findings on the biotechnology 
industry in particular. Section 3 describes the data and the variables of interest. The method of 
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analysis is discussed in detail and a regression model presented. Section 4 presents our results and 
section 5 finalise the paper.    
  
Theory 
Innovation is a combination of ideas and capabilities that previously have not been combined. This 
definition has been adopted by among others Nelson and Winter (1982), Katila and Ahuja (2002) 
and Flemming and Sorenson(2004). Innovation is therefore said to be an integration of previously 
separate bodies of knowledge. Recent models of open innovation highlight the importance of 
relying on external sources of knowledge (see among others von Hippel (1988): Lundvall (1992) 
and Chesbrough (2003). In studying start-ups Baum et al (2000) perhaps put it best by saying don’t 
go it alone. Accordingly it is vital for a firm to search among external sources to be successful in its 
innovative activities.  
 
However, the game is not only about being innovative. It is one thing to innovate in technologies 
the firm previously has used in its innovation activities or in which it otherwise have experience in. 
Another is to develop new capabilities or new ideas in areas in which the firm have little or no 
experience or particular knowledge. The competitiveness of firms is not only shaped by its ability to 
integrate and build upon its current competencies, but also its ability to develop new capabilities 
(Teece, Pisano, & Shuen, 1997).  
 
Innovative activities that go beyond the technological boundaries of the firm have been termed 
exploratory innovation. It involves expanding the innovative scope of the firms thereby meaning 
introducing innovations in technological areas in which the firm previously have not been 
innovating.  
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An innovation strategy that involves exploration is highly risky. Contrary to an exploitation strategy 
it involves experimentation and uncertainty and the returns from exploration are usually more 
remote in time. It is therefore often beneficial to combine exploration and exploitation strategies 
(March, 1991; Levinthal & March, 1993; Burgelman, 1994; Gavetti and Levinthal, 2000). It is 
fundamental to overcome innovation or learning myopia in order to become successful in 
exploratory innovation activities. In particular it is important to overcome what Levinthal and 
March (1993) call temporal myopia. Firms become rather specialised in distinctive competencies 
and niches resulting in knowledge boundaries. Competencies outside its boundaries become highly 
difficult to obtain. Firms experience a lock-in effect which may lead to substantial long-run 
vulnerability in terms of its competitiveness. From a transaction cost point of view temporal myopia 
represent a cost which the firm needs to pay if it wishes to break free of the lock-in to specific 
capabilities and innovation trajectories.      
 
To achieve the combination of exploitation and exploration it is necessary to jump the hurdle of 
innovation myopia and make exploratory strategies less uncertain and risky. Levinthal and March’s 
(1993) solution to temporal myopia is a flow of competences between organisation where 
individuals and sources of capital continuously are exchanged between organisations. However, 
such an exchange of competencies may often be of limited value in terms of promoting an 
exploratory search. Organisations may be reluctant to provide the necessary autonomy to new 
additions to staff in which case experimentation with different ways of thinking is highly unlikely.   
  
Alternative ways to break away from the liability of temporary myopia is to search externally and 
engage in collaborative activities. Collaboration has become one of the central elements in the study 
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of innovation and innovation performance. Collaborating firms are clear candidates of becoming 
novel innovators and therefore introduce products that are new to the market rather than simply new 
to the firm (Tether, 2002). Such findings suggest collaboration to be an engine for exploratory 
search rather than a part of an exploitation strategy. 
 
Collaboration is induced by accessibility of resources which is not otherwise available to the firm 
(Ahuja, 2000). The firm is much less likely to engage in collaboration if the resource obtainable is 
available within the firm or on the market. Linking this with the notion of exploratory strategies, 
collaboration on innovative activities may be a way to explore other parts of the knowledge 
landscape and enjoy the advantage of having more opportunities through an increased number of 
possible new combinations of existing knowledge bodies. However, not only does it suggest the 
firm becomes more innovative, but it also imply that firms through collaboration are able to extend 
their innovative scope. Collaborative partners become the firm’s engines for innovating in 
knowledge bodies or technological areas in which it otherwise lack competences. Collaborating is 
means to which the firm is able innovate beyond its technological boundaries and hence break away 
from its innovation myopia.  
 
The Biotech industry  
The biotechnology industry has been studied with respect to collaboration and innovation in several 
papers. Powell et al. (1996) emphasised the importance of the network of interorganizational 
relationship in shaping the locus of innovation. They emphasised that firms in the biotechnology 
industry in particular may be subject to Baum and Olivers (1992) liability of unconnectedness. 
Powell et al. suggest firms suffering from this particular liability and hence only have few ties are 
becoming increasingly rare and thereby relating the ability to build a network of collaborators to 
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survival. In particular, Powell et al. accentuates the role of collaborating with other dedicated 
biotechnology firms.  
 
In a study on the effect of alliance network compositions on the performance of biotechnology start-
ups, Baum et al. (2000) found significant differences according to the type of partner with whom 
the alliance is formed. Their analysis suggests both upstream and downstream alliances and a 
diversified network to support the initial performance of the biotech start-up. These findings define 
a starting point for new studies of partnerships and the effect on the innovative activities of the 
biotechnology firm. It is essential to investigate the type of partners and to insist on aligning this to 
the biotechnology in question. Firms in small molecules biotechnology may need to form alliances 
with one type of collaborative partner while firms in large molecules biotechnology may find it 
beneficiary to form an alliance with another type.   
 
Also investigating the biotechnology industry, Gilsing and Nooteboom (2006) emphasise how 
exploitation and exploration builds upon each other. Dynamics of innovation shifts according to a 
cycle of discovery in which different phases may be overlapping. Both sectoral and firm level 
dynamics play a role in shaping the transition from one phase to another. Among other things 
Gilsing and Nooteboom emphasise the change in the mindsets of the firms. Moving along the cycle 
of discovery also shift the mindset of the firm with respect to innovative activities. The exploratory 
stage requires an in-depth understanding of stand-alone, science-based knowledge. The exploitation 
oriented stages does so to a lesser extend. A shift between these two innovation regimes has 
significant implications for the network structure of a given firm. A dense network and creating a 
network with high level of diversity on the input side of the knowledge creation process are almost 
necessities in an exploratory innovation regime. Gilsing and Nooteboom also stress that the 
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composition of partner types in networks should change as the innovation regime shift stage in the 
cycle of discovery.  
 
Gilsing and Nooteboom’s findings suggest it to be important to split bio-technology into sub-
samples. Because firm level dynamics play a significant role in shaping the shift between 
exploratory to exploitation regimes, it is possible that the shift between different phases takes place 
on a lower level of aggregation than the biotechnology industry level.    
  
Finally Pisano (1990) discussed the difference between in-house and external R&D. He emphasised 
that internalizing new biotechnology capabilities may be costly. This may in particular be supported 
by the notion of learning myopia in which the lock-in effect makes it more difficult to move into 
new areas of research and hence represent a high cost of transformation. Pisano points out that 
biotechnology firms consequently may choose to procure a large share of their R&D outside the 
firm regardless of a long history of successful R&D activities. Such a strategy enables the firm to 
move into new product markets and hence extend its innovative scope. Outsourcing and acquisition 
of patents is therefore an alternative way to cross technological boundaries which otherwise is 
costly for the firm to attempt if strictly done so in-house. 
 
Data, method and Descriptive Statistics 
The data 
The aim of the paper is to study how different types of collaboration partners and external R&D 
activities shape the innovative scope of firms. We use the SCANBIT database to study these 
questions. SCANBIT is continuously developed and maintained by Research Centre on Biotech 
Business at Copenhagen Business School. It contains a substantial share of the Scandinavian 
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Biotech industry only missing a limited number of micro-firms. We extracted the Danish and 
Swedish firms concentrating on these two countries and hence leaving out Norway whose 
biotechnology industry is somewhat less developed. The dataset operates on two levels of 
measurement. It contains firm level panel data including such variables like firm size, firm age, and 
firm science base. This is combined with patent data for each of the firms included in the dataset. 
The dataset has proven useful and acceptable in previous publications (see e.g. Valentin and Jensen 
(2007) and Valentin et al. (2007))  
 
In order for the database to be consistent throughout the years, we controlled for mergers and 
acquisitions by considering the merged firms as a single firm in the entire database. By doing that, 
we do not consider an expansion of a technological boundary brought about by a merger or an 
acquisition of another firm as an extension of the innovative scope of the firm. Additionally we 
have cleaned the dataset for co-inventors from foreign subsidiaries. We consider foreign 
subsidiaries as a business extension of the firm rather than a technological extension.     
 
Dependent variable 
We exploit the International Patent Classification (IPC) code attached to each patent to identify the 
innovation scope of the firms. IPC codes has been used for similar purposes by among others Jaffe 
(1986; 1989), Granstrand et al.(1997), Patel and Pavitt (1997; 2000) and Dahlgren et al. (2004).  We 
follow the approach by Dahlgren et al. by calculating a revised concentric index first introduced by 
Caves et al. (1980). This measure use the three digit IPC code by comparing patents two by two. 
We first compare the first digit if the IPC and assign the value 1 if the two differs. If these are 
similar we compare the second digit and assign the value 0.5 if they differ. Finally we compare the 
third digit of the IPC codes of the patents if the first two digits were equal. We assign the value 0.25 
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if these differ. Otherwise the patents are considered to be in the same technological classification 
and hence assign a zero innovation scope value between those two particular patents.1 Dahlgren et 
al. compared each patent with all previous patents and used the average deviation of the patent to 
indicate to what extend the patent differed in the IPC code compared to other patents applied for by 
the firm. By taking the average value the indices may be compared regardless of the number of 
patents the firms has applied for at any given point in time.   
 
Rather than comparing each patent application with the firms previous patent applications like 
Dahlgren et al., we measure how each patents deviates from all other patent application the firm has 
filed regardless of time. There are three reasons for doing this. Firstly, we would loose a number of 
observations had we taken time into account. First time patent applicants would otherwise be 
disregarded because there would be no previous patent to compare with. Secondly, each patent with 
the same firm is subject to the same pool of objects of comparison. We would be comparing a 
measure based on a different sample had we limited the comparisons to being backwards looking. 
The second patent application would only be compared with one other patent while the 10th patent 
would be compared to a pool of nine patents. While taking the mean deviation goes a long way to 
correct this, it will nevertheless be a partial adjustment. A firm that has many patents is more likely 
to have exhausted the pool of possible patent classes while a firm that only holds a limited number 
of patents is less likely to have exhausted patent classifications. By measuring how much on 
average each patent deviates from the remaining patents of the firm disregarding time, we maximize 
the number of patents comparisons of each firm. We hope by doing so the possible bias created by 
differences in extend of patenting will be minimized. Thirdly, by comparing each patent by all other 
patents rather than just previous patents we ensure that the comparisons pool exhibits a much 
clearer picture of the in-house technological boundaries rather than simply a time specific pattern.    
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This dependent variable permits us to studying the factors that enable firms to apply for a patent 
that deviates from the firms’ other patent applications. It may be perceived as a technological 
distance measure between a given patent and the rest of the firms patent port folio. The variable 
therefore allows us to investigate practices that extend the innovative scope of the firm and hence 
drive technological heterogeneity. 
 
Explanatory variables 
The analysis contains two groups of explanatory variables. The first group of explanatory variables 
relates to collaboration. We measure collaboration by identifying the affiliation of the authors of the 
patent applications. This enables us to say if there has been a formal collaboration between the firm 
and other organisation. We operate with three types of organisations; pharmaceutical firms, 
universities, and other dedicated biotech firms. This provides three dummy variables attached to 
each patent. These three dummies allow us to look for different types of partners and their role in 
shaping the innovative scope of the firm. 
 
The second batch of explanatory variables expresses whether the patent has been acquired or the 
firm has outsourced their R&D. We categorise patent applications with no in house authors as 
outsourced if the firm itself is the assignee. Contrary an acquired patent is a patent application 
where none of the authors are affiliated to the firm and the firm itself is not an assignee on the 
patent. These variables are used to test the notion that external R&D allow firms to patent in 
technological areas which are outside the boundary of the firm and which the firm find to be too 
costly to embark on internally.  
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We also include a number of control variables. The first captures the number of inventors and is 
based on the number of authors on the patent application. Multiple authors may suggest a more 
extensive opportunity landscape being searched and circumstances which are not associated to the 
explanatory variables but which may be correlated and hence otherwise be a source of spurious 
correlation in the regression analysis. We also add a firm size variable hoping to capture the 
availability of extensive complementary assets within the firm which may permit a broader search 
parameter regardless of the collaborative behaviour of the firm. By introducing year fixed effects, 
we ensure the results cannot be attributed to changes in the innovative behaviour of the 
Scandinavian biotech industry across time. Finally we will include a dummy for whether the firm in 
question is operating in large or small molecule biotechnologies.  
 
The method 
Figure 1 is a histogram of the heterogeneity index and reveals that its empirical distribution is not 
normally distributed.2 It would therefore be dubious to use the traditional regression techniques as a 
tool of analysis. Alternatively we categorised the patents in two. Patents that contributes with a high 
level of innovative scope and patents that contributes with a low level of innovative scope. We used 
the mean innovation scope index across all patents and all firms as a classification point.3 This 
leaves us with a binomial dependent variable dictating a logistic regression technique.  
      
< INSERT FIGURE 1 ABOUT HERE > 
 
Some patent applications are filed by the same firm and may therefore not be independent 
observations. A firm exhibiting a high level of innovative scope in one patent may also exhibit a 
high level of innovative scope in another patent. There are two reasons for this. First, the calculation 
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of the heterogeneity index of one patent dependent on another patent taken by the same firm and 
vice versa. So heterogeneity in the first leads unavoidably to increased heterogeneity in the second. 
Secondly, it may be an integrated part of a firm strategy to search broadly for new intellectual assets 
and hence be an integrated goal of the firm to have a high heterogeneity across its patents 
applications. Violating the independency between observations assumption may render the 
regression estimates biased if left unattended. To avoid bias attributed to this particular feature of 
the data we relax the assumption of independence between observations within firms and only treat 
observations from different firms as truly independent. Put differently, we run cluster corrected 
estimations and thereby obtain adjust the standard errors for intra-group correlations. This also 
provides robust estimates consistent regardless of heteroskedasticity.  
 
 
< INSERT FIGURE 2 ABOUT HERE > 
 
Figure 2 illustrate the use of collaborative partners in patent activities when separating the sample 
into large and small molecules biotech companies. The three types of collaborative partners are 
represented in both samples and the frequency of collaboration with the three types of partners rank 
equally between the two sub-samples. However, the relative percentages suggest there to be some 
difference in the usage of different types of collaborative partners. It is for instance relatively more 
likely that a firm in small molecule research use other dedicated biotechnology firms compared to 
universities than large molecules research firms. With this in mind we tested the difference in the 
innovative scope index across large and mall molecules research firms using a simple t-test. We 
found the small molecules research firms to generate higher innovative scope than their large 
molecule counterparts. These facts may suggest differences in the dynamics of collaborative 
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behaviour and the effects on the innovative scope when comparing large and small molecules 
research firms. This may be the result of a difference in the relative strength of exploration and 
exploitation innovation strategies between the two sub-samples. We accordingly investigate the 
differences between the two sub-samples in the results section. This also enables us to say 
something about the necessity to align the type of partner with the science base of the firm.        
 
Finally we found no multicollinearity problems in the estimated models. We report the associated 
maximum variance inflation factors for each model in the regression table showing it never exceeds 
a critical 10.  
 
Descriptive Statistics 
Table 1 contains the descriptive statistics of the variables included in the model. It also contains the 
correlation coefficients between these variables. From Table 1 it is obvious that collaboration with 
other dedicated biotechnology firms is the predominant form of collaboration in the Danish and 
Swedish bio-technology industry. The firms do not seem to be discouraged to collaborate with 
potential rivals. This may suggest using other dedicated biotechnology firms allows the firm to 
shifts its innovative locus as suggested by Powell et al. (1996). The second most frequent type of 
partner is universities with only a bit less than 14% of the firms collaborating with pharmaceutical 
firms.   
 
< INSERT TABLE 1 ABOUT HERE > 
 
The descriptive statistics also reveal that more firms outsource their innovative activities rather than 
acquire a patent. Only about 3.5% of the observations are patents that were acquired while more 
 16
than 33% were outsourced patent applications. A bit more than half of the observations are patents 
applied for by firms operating in small molecules bio-technology. Finally the correlation 
coefficients confirm that the analysis do not suffer multicollinearity. Many of the coefficients are 
highly significant. But only between outsourcing and collaboration with other dedicated 
biopharmaceuticals do we see a high correlation coefficient (0.77).    
 
Results 
The results of the regression are summarized in table 2. Three regressions are shown. The first 
includes all types of biotech firms while the last two only investigate firms operating in large and 
small molecules respectively. This allows us to compare the overall pattern of the biotech industry 
to that of two different science bases and consequently study whether aligning the type of partner to 
the science base is of importance.   
 
The regression using the unsplit sample reveals a strong support for collaboration being a driver of 
innovative scope. The variables indicating collaborating with pharmaceutical firms and 
collaborating with universities exhibits positive significant parameter estimates. The parameters 
suggest collaborating with these two types of partners more than double the likelihood of expanding 
the innovative scope of the firm. Likewise we find support that acquired patents and patents from 
outsourced innovation activities extends the innovative scope of the firm. Outsourcing of 
technological innovation activities and acquiring patents from externals partners is hence used as a 
strategy for moving into new technologies rather than doing research in knowledge areas in which 
the firm is already operating.         
 
< INSERT TABLE 2 ABOUT HERE > 
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Looking to the split sample regressions we see noteworthy differences between patents applied for 
by firms in large molecules biotechnology compared to firms in small molecules biotechnology. 
With respect to collaboration, the small molecules biotechnology firm regression confirms the 
results of the findings of the regression using all observations. Collaborating with pharmaceutical 
firms and universities extend the innovative scope of the firm. However, the pattern is some what 
different when studying patents applied for by large molecules biotechnology firms. In this case 
collaborating with universities is insignificant while collaborating with other dedicated 
biotechnology firms is significant. In this particular science base of the biotechnology industry, we 
see a distinct and separate pattern from that of the overall biotechnology results indicating the 
importance of aligning the type of collaboration partners with the science base.  
 
The regressions also reveal a difference in the way patent acquisitions and technology outsourcing 
is used. While firms in large molecules biotechnology use these two means to extend their 
innovative scope, firms in small molecules biotechnology do not rely on these measures to move 
into new technologies.     
 
With respect to the controls variables, large firms are significantly more likely to extend their 
innovative scope than small firm. Large firms have complementary assets which enables them to 
extend their search boundaries beyond their current technologies.   
 
Discussion 
Several studies have shown formal collaboration to be of major importance in a firm’s struggle to 
become innovative. Collaborating partners provide knowledge and know-how to the innovation 
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process which positively influence the likelihood of a firm’s innovation success rate. However, 
rather than simply facilitating innovation in the firm’s own area of research, external partners 
contribute with knowledge which is outside the scope of the firm’s expertise. As Pisano (1990) 
emphasised, partnering may be a relative inexpensive way to get access to knowledge which the 
firm otherwise do not have access to in-house. By collaborating with other organizations and 
institutions, the firm broadens its innovative scope by moving in new areas of patenting.  
 
Studying the Danish and Swedish biotechnology industry, we find support for the proposition that 
collaboration extends the innovative scope of the firm. In particular we found collaborating with 
pharmaceutical firms and universities extends the range of technologies the firm operates in. These 
particular two types of partners seem either deliberately to be used to move into new technologies, 
or unintentionally to provide particular types of knowledge that extends the firm’s innovative scope. 
  
We also found that the firm should align the partner type to its science base. We established that the 
type of partners contributing significantly to extending the innovative scope of the firm differed 
between firms specialised in large and small molecules biotechnology. While small molecule firms 
exhibit similar patterns to those found studying the entire sample of biotech firms, firms operating 
in large molecule biotechnology seem to benefit from other dedicated biotechnology firms rather 
than from universities. The two sub-industries of biotechnology may be in different stages of the 
cycle of discovery (Gilsing and Nooteboom, 2006) and therefore need different knowledge input to 
expand its knowledge boundary and be classified as extending its innovative scope. .     
 
Both acquisition and outsourcing was found to facilitate innovative scope. In particular firms in the 
large molecules biotechnologies exhibit significant parameter estimates for external innovation 
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activities. In the spirit of the work by Pisano (1990), this might suggest these firm find it to costly to 
invest in in-house capabilities that would allow them to move into new technological areas and 
hence extend their innovative scope. Instead firms in large molecules biotechnologies find 
outsourcing and acquisition of patents to be the preferred way to expand their innovative scope.   
 
Future research on the innovative scope of the firm could productively explore how the innovative 
scope of firms changes in accordance with shift in the focus on exploration versus exploitation. 
However, before we can explore this, it is necessary to investigate the interaction between 
exploitation, exploration, collaboration, and the types of collaborative partners. A more dynamics 
investigation into this relationship may prove beneficiary and have major implications for 
understanding how and when a firm should try to expand its innovative scope. 
 
Considering the rather crude division of collaborative partners into three categories also represent 
some potential for future research. Additionally, we find it to be of importance to investigate to 
what extend these results are governed by the disaggregation into large and small molecules. Using 
a more comprehensive data may open up for the possibility to disaggregate even further and find a 
different pattern than the one found in these data? Furthermore we find it to be of importance to 
study whether the results rely on our measure of innovative scope? Creating a new index for 
accessing the technology in which a given patent may be classified may prove beneficiary. Relying 
on IPC codes is at any rate at least partially subjective and may therefore have an impact on our 
results. We therefore propose future work on developing methods for categorising patents into 
technological groups according to their patent application descriptions.  Finally, we suggest 
extending the analysis into other industries and study to what degree our findings are robust across 
industry borders. 
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FIGURES 
Figure 1: Density plot of Heterogeneity Index and its associated normal density function.               
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Figure 2: Share of patents that has an author with external affiliation. Differences between large and 
small molecule biotech business considered.   
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TABLES 
Table 1: Descriptive statistics and Pearson’s Correlation Coefficients (N=781) 
 
                                              |    Mean  Std.Dev.  |       1        2        3        4        5        6        7        8   
----------------------------------------------+--------------------+----------------------------------------------------------------------- 
                                              |                    | 
 1. Innovative Scope                          |   0.678    0.467   |     
                                              |                    |    
                                              |                    | 
 2. Collaborating with Pharmaceutical         |   0.137    0.344   |  0.1151 
                                              |                    |  0.0013 
                                              |                    | 
 3. Collaborating with University             |   0.458    0.499   |  0.1260  -0.0447  
                                              |                    |  0.0004   0.2126 
                                              |                    | 
 4. Collaborating with Dedicated Biotech Firm |   0,732    0,443   | -0.1193  -0.1122  -0.3622  
                                              |                    |  0.0008   0.0017   0.0000 
                                              |                    | 
 5. Acquired Patent                           |   0,035    0,183   |  0.0554   0.0876   0.0935  -0.1071 
                                              |                    |  0.1223   0.0144   0.0090   0.0027  
                                              |                    | 
 6. Outsourced Patent                         |   0,332    0,471   |  0.1768   0.0275   0.2976  -0.7720  -0.1335 
                                              |                    |  0.0000   0.4438   0.0000   0.0000   0.0002 
                                              |                    | 
 7. Log(No. of inventors)                     |   1,141    0,644   | -0.0243   0.2602   0.2222   0.2401   0.1454  -0.2572 
                                              |                    |  0.4987   0.0000   0.0000   0.0000   0.0000   0.0000 
                                              |                    | 
 8. Log(No. of Employees)                     |   3,671    1,566   |  0.1076   0.2001  -0.2463   0.2334  -0.0772  -0.2864   0.0998 
                                              |                    |  0.0026   0.0000   0.0000   0.0000   0.0310   0.0000   0.0053 
                                              |                    | 
 9. Small Molecule Firm                       |   0,535    0,499   | -0.0650   0.0807  -0.0921   0.1203  -0.0624  -0.1663   0.0607   0.2465 
                                              |                    |  0.0697   0.0243   0.0100   0.0008   0.0818   0.0000   0.0903   0.0000 
----------------------------------------------+--------------------+----------------------------------------------------------------------- 
 
Note: Figures below correlation coefficients are the corresponding P-values. 
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Table 2: Determinants of Innovative Scope, results of logistic regressions with robust and cluster 
corrected standard errors  
 
                                                     All         Large         Small    
                                               Molecules     Molecules     Molecules    
Collaborating with Pharmaceutical                  0.835**       1.293*        0.998**  
                                                 [0.379]       [0.698]       [0.470]    
Collaborating with University                      0.729**       0.370         0.809**  
                                                 [0.313]       [0.419]       [0.408]    
Collaborating with Dedicated Biotech Firm          1.138         1.867**       0.609    
                                                 [0.729]       [0.785]       [1.028]    
Acquired Patent                                    1.847*        2.184**       1.859    
                                                 [1.042]       [1.106]       [1.351]    
Outsourced Patent                                  1.855**       2.991***      1.004    
                                                 [0.790]       [0.779]       [1.039]    
Log(No. of inventors)                             -0.300        -0.303        -0.240    
                                                 [0.233]       [0.256]       [0.379]    
Log(Employees)                                     0.316*        0.020         0.566**  
                                                 [0.177]       [0.236]       [0.251]    
Small Molecule Firm                               -0.224                                
                                                 [0.523]                                
 
Year Fixed Effects              Yes           Yes           Yes 
Number of Observations                               780           363           417    
Number of firms                                       73            44            29    
    
Maximum VIF                                        6.240         3.070         3.340 
Pseudo R_square                                    0.100         0.135         0.147    
Chi-Square                                        32.370***     92.861***     67.615*** 
Bayesian Information Criterion (BIC)             995.224       472.138       557.343    
 
* p<0.1, ** p<0.05, *** p<0.01 
 
 
                                                 
1 We tested whether different value combination would entail different results. Comparing (0.50,0.25) with (0.66,0.33), 
(0.60,0.30), (0.75,0.50), and (0.75,0.25) yielded similar results suggesting the results to be robust with respect to the 
chosen weighting values between different levels of IPC code levels.   
2 This was supported by a Kolmogorov-Smirnov normality test. 
3 We tested whether the results were sensitive to using the median as opposed to the mean as a divisional level between 
high and low level heterogeneity piloting patents. We found no substantial differences between the two approaches.  
